Femme et Homme
- | Pays : -
- | Organes : -
- | Spécialités : -
Extrait
To define the objective response rate associated with the administration of vorinostat in combination with bortezomib to patients with relapsed or refractory multiple myeloma after at least 2 prior treatment regimens, who meet both of the following conditions: Refractory to Bortezomib (administered either alone or in combination with other agents); defined as no response on prior bortzeomib-containing regimens or progression on or within 60 days of a bortezomib-containing regimen. Relapsed, refractory, intolerant, and/or ineligible (in the opinion of the Investigator) to other therapies, including an IMid (thalidomide OR lenalidomide).
Critère d'inclusion
- Multiple myeloma